Zydus
dedicated to life

Cadila
Healthcare Limited

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

October 7, 2010

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001.

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051.

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015.

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam

We are please to inform you that the Company has received an approval from USFDA to market for Losratan Potassium tablets (25mg, 50mg and 100 mg) and Losratan Potassium + Hydrochlorothiazide tablets (50/12.5 mg and 100/25mg) in US market.

We enclose herewith a copy of press release dated October 7, 2010 titled **"Zydus Cadila receives USFDA approval for Losratan Potassium tabs and Losratan Potassium + HCTZ tabs "** to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,
FOR **CADILA HEALTHCARE LIMITED**

UPEN H. SHAH
Company Secretary

Encl.: As above.

Zydus Cadila receives USFDA approval for Losartan Potassium tabs and Losartan Potassium + HCTZ tabs

Launches products on the very same day

Ahmedabad, October 07, 2010

Zydus Cadila has received an approval from the USFDA to market Losartan Potassium tablets (25mg, 50mg and 100mg) and Losartan Potassium + Hydrochlorothiazide tablets (50/12.5mg and 100/25mg) in the US market. Gaining a significant advantage, Zydus Pharmaceuticals (USA) Inc., launched both products on the very same day after receiving approvals from the USFDA.

The drugs fall in the anti-hypertensive segment and are used for treating high blood pressure. The sales of Losartan Potassium tablets in the US market is estimated at USD 1.3 bn and that of Losartan Potassium + Hydrochlorothiazide tablets is estimated at USD 944 mn in 2010 as per NDC Health.

The group has 56 approvals and has so far filed 113 ANDAs since the commencement of filing process in FY 2003-04.

***

For further information please contact :
The Corporate Communications Department

'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2365/66 www.zyduscadila.com